

### Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

#### **Listing of Claims:**

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Currently Amended) A method for the treatment ~~or prophylaxis~~ of multiple sclerosis (MS) comprising administering ~~a therapeutically effective amount of an inhibitor of IL-17 activity~~ to a patient in need thereof a therapeutically effective amount of anti-IL-17 antibody or anti-IL-17 antibody fragment.
11. (Withdrawn) The method according to claim 10, wherein the inhibitor is a small molecule.
12. (Withdrawn) The method according to claim 10, wherein the inhibitor is a nucleic acid.
13. (Canceled)
14. (Currently Amended) The method according to claim ~~13~~ 10 wherein the antibody or antibody fragment is monoclonal, polyclonal, chimeric, humanized, or bispecific.

15. (Currently Amended) The method according to claim ~~43~~ 10 wherein the antibody fragment is a Fab, Fab', F(ab')<sub>2</sub>, scFv or epitope binding fragment.
16. (Currently Amended) The method according to claim ~~43~~ 10 wherein the antibody or antibody fragment is conjugated to one or more effector molecule(s).
17. (Cancelled)
18. (Withdrawn) The method according to claim 13 wherein the antibody or antibody fragment binds to IL-17R.
19. (Currently Amended) The method according to claim 10 wherein the ~~inhibitor of IL-17 activity~~ anti-IL-17 antibody or anti-IL-17 antibody fragment is administered in combination with one or more other therapeutically active compounds.